טוען...
Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?
The advent of sodium-glucose cotransporter 2 (SGLT2) inhibitors represents a major advance for people with type 2 diabetes (T2DM) and chronic kidney disease (CKD). The results of the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial have cle...
שמור ב:
| הוצא לאור ב: | Nephrol Dial Transplant |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Oxford University Press
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6993192/ https://ncbi.nlm.nih.gov/pubmed/32003833 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndt/gfz252 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|